Phase 2 Chronic Kidney Disease Trial, Recruiting NCT05719714 Sponsor: Northwestern University Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 2 Chronic Kidney Disease Trial, Recruiting

NCT05719714
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 18 years of age
  • People whose kidneys are working at a reduced but not severely low level (a specific kidney function test score between 25 and 60, which a doctor can measure)
  • People who have been on stable, unchanged doses of water pills (diuretics) and/or certain blood pressure medications (ACE inhibitors or ARBs)
  • People whose heart scans and/or exercise breathing tests show signs of a specific type of early-stage heart condition where the heart pumps normally but does not relax properly, without yet having obvious symptoms

Who may not be able to join:

  • People who have diabetes or have had it in the past
  • People who have had a procedure to open blocked heart arteries within the last 6 months
  • People who have a significant problem with one or more of their heart valves
  • People who have serious lung disease that requires them to use oxygen at home
  • People who experience chest pain (angina)
  • People who have reduced blood flow to the heart muscle that has not been treated with a procedure
  • People whose blood pressure is below 100 or above 180 mmHg
  • People who are pregnant
  • People who already have noticeable symptoms of heart failure
  • People who have a history of certain whole-body diseases known to cause heart problems, such as amyloidosis or sarcoidosis
  • People who have a physical condition affecting their muscles or joints that would prevent them from completing heart and exercise tests
  • People who currently have active cancer
  • People who are taking medications that suppress the immune system
  • People whose heart scans show that their heart's pumping strength is below a certain level (ejection fraction under 50%)
  • People who are currently taking a type of diabetes/kidney medication known as an SGLT2 inhibitor
  • People who have had an allergic reaction to an SGLT2 inhibitor
  • People who have a pre-existing liver condition
  • People whose liver blood test results are more than three times higher than the normal range (confirm with trial site)
  • People who have a history of frequent urinary tract infections, or who have had a urinary tract infection in the last 3 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Rupal Mehta, MD, Northwestern Univeristy

Phone: (312) 503-1536

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
16 January 2024
Est. completion
30 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Left ventricular longitudinal strain (LVLS); Peak VO2 (oxygen consumption); Circulating plasma metabolite concentrations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov